Molloy Eleanor J
Department of Neonatology, National Maternity Hospital, Dublin, Ireland.
Recent Pat Antiinfect Drug Discov. 2009 Jan;4(1):51-6. doi: 10.2174/157489109787236292.
The Triggering Receptors Expressed on Myeloid cells (TREM) are a family of activating receptors with some homology with activating natural killer cell receptors. TREM-1 is an activating receptor on neutrophils and monocytes that plays an important role in the amplification of inflammation. TREM-1 blockade significantly decreases mortality from bacterial sepsis. Altered TREM-1 expression on neutrophils in response to bacterial stimuli may be an important factor in susceptibility to bacterial infection. However the natural TREM-1 ligand is unknown although Toll-like receptor agonists stimulate TREM-1 upregulation and function. TREM-2 regulates dendritic cell function by inducing CCR7 expression on peripheral dendritic cells and directing them from the periphery to the draining lymph node. These receptors may potentially be manipulated to alter the inflammatory response to severe sepsis and chronic inflammation and possible therapies and patents are explored in this review.
髓系细胞表达的触发受体(TREM)是一类激活受体,与激活型自然杀伤细胞受体有一定同源性。TREM-1是中性粒细胞和单核细胞上的一种激活受体,在炎症放大过程中起重要作用。阻断TREM-1可显著降低细菌性败血症的死亡率。中性粒细胞对细菌刺激的TREM-1表达改变可能是易患细菌感染的一个重要因素。然而,尽管Toll样受体激动剂可刺激TREM-1上调和发挥功能,但其天然配体尚不清楚。TREM-2通过诱导外周树突状细胞上CCR7的表达并将其从外周导向引流淋巴结来调节树突状细胞功能。这些受体有可能被调控以改变对严重脓毒症和慢性炎症的炎症反应,本综述探讨了可能的治疗方法和专利。